Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
In primates, activity in the visual cortex—a part of the brain that processes signals from the eyes—is largely unaffected by the body’s own movements, according to a new study from scientists at the National Eye Institute (NEI).
The K99/R00 provides a runway for postdocs seeking to transition from mentored positions to tenure track positions at academic institutions in the U.S.
Ruchi Sharma, Ph.D., a staff scientist in the NEI Ocular and Stem Cell Translational Section, received an award from the Knights Templar Eye Foundation (KTEF), a charity sponsored by the Grand Encampment of Knights Templar.
Nitin Verma visited NIH and shared his lifetime perspective on the delivery of vision care to underserved populations in the Australia/South Pacific region—roughly 50-million people scattered across vast stretches of land and ocean.
Researchers have successfully transplanted human microglia into mouse retina to create a model for studying eye disease treatments, such as diabetic retinopathy, glaucoma and age-related macular degeneration.
The Noelin family of secreted proteins bind to the external portion of AMPA glutamate receptors and stabilize them on the neuronal cellular membrane, a process necessary for transmission of full-strength signals between neurons.
Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years